Shares of Amyris, Inc. (NASDAQ:AMRS) dropped 5.1% during trading on Friday . The stock traded as low as $3.55 and last traded at $3.55. Approximately 606,428 shares traded hands during mid-day trading, an increase of 100% from the average daily volume of 303,202 shares. The stock had previously closed at $3.74.

AMRS has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Amyris in a research report on Tuesday, May 23rd. ValuEngine lowered shares of Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company set a $4.00 price objective on shares of Amyris and gave the stock a “hold” rating in a research report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $30.25.

The firm has a 50-day moving average of $2.88 and a 200-day moving average of $4.88. The firm’s market capitalization is $133.50 million.

Amyris (NASDAQ:AMRS) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by ($0.35). The business had revenue of $25.68 million for the quarter, compared to analyst estimates of $23.68 million. The business’s revenue for the quarter was up 167.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) EPS. Analysts expect that Amyris, Inc. will post ($3.32) EPS for the current fiscal year.

An institutional investor recently raised its position in Amyris stock. Bank of New York Mellon Corp lifted its holdings in Amyris, Inc. (NASDAQ:AMRS) by 16.3% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,768 shares of the biotechnology company’s stock after purchasing an additional 4,603 shares during the period. Bank of New York Mellon Corp owned about 0.17% of Amyris worth $104,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amyris, Inc. (AMRS) Shares Down 5.1%” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.